ADVA
28.1.2021 09:02:09 CET | Business Wire | Press release
ADVA (FSE: ADV) today announced that the Saudi Telecom Company (STC) is rolling out on-demand virtual services using ADVA’s Ensemble suite of network functions virtualization (NFV) technologies. The new universal CPE (uCPE) offering is built on the Dell EMC Networking Virtual Edge Platform (VEP) 1405 series running ADVA’s Ensemble Edge Cloud NFV suite. Enterprise customers of STC, the largest IT service provider in the Middle East, will be able to quickly and easily access virtual services, including routing, firewall, WAN optimization, IoT and voice applications. With the industry’s largest ecosystem of virtual network functions (VNFs) to choose from, managed service customers can automatically enable new applications and services without any financial risk.
“Today’s enterprises need to be agile. They require the freedom to mix and match the latest cloud technologies to seize new revenue opportunities in an instant. That’s what our new uCPE service is all about. It eliminates vendor lock-in and lets our clients experiment with best-in-class solutions that fit their specific needs and ambitions,” said Fahad A. Alhajeri, VP, digital solutions, STC. “By giving our customers quick and secure access to an unrivalled range of multi-vendor virtual technologies, we’re unleashing the full potential of businesses in this region. With the help of ADVA’s Ensemble NFV technology, we’re forging a path for our customers to a cloud-based future of on-demand services and rapid innovation.”
STC’s new uCPE offering enables businesses across the Middle East to select virtual products from the Ensemble Harmony Ecosystem , a unique multi-vendor environment with unparalleled variety and choice. It’s built on the Dell EMC Networking VEP 1405 series, a compact, low-power uCPE appliance purpose-built to host VNFs and ideal for demanding SD-WAN applications. With ADVA’s Ensemble Connector as the NFVI platform, multiple VNFs can run on a single uCPE. Other key components include Ensemble Orchestrator and Virtualization Director, which provide a simple and effective management and orchestration (MANO) architecture, empowering STC to roll out secure virtualized services at scale.
“STC’s uCPE service is ideal for connecting the enterprise to the cloud. Now businesses throughout the Middle East can leverage the power of virtualization and choose from the market’s widest range of onboarded commercial VNFs,” commented James Buchanan, GM, Edge Cloud, ADVA. “Our Ensemble suite’s MANO capabilities support the rollout of secure virtualized service across multiple locations with complete flexibility and scale. And, thanks to our Ensemble Connector’s zero-touch provisioning, STC can ship uCPE to a customer site and provision it securely with no need for technicians. With such rapid deployments and agile service creation at the network edge, STC is leading the way to the managed services of tomorrow.”
“By utilizing our Virtual Edge Platform 1405 series and ADVA’s Ensemble software, STC is giving its customers a simple way to respond to shifting industry demand,” said Drew Schulke, VP, Dell EMC Networking, Dell Technologies. “Working with ADVA, we’re empowering STC and its customers to digitalize their infrastructures. Now they can deploy solutions at the click of a mouse and harness advanced tools for boosting security, reducing costs and improving end-user customer experience.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com
.
About STC
“Solutions by STC” is one of the largest technology and communications services providers in the Middle East. The company has a range of products and services that address the needs of consumers and businesses of all sizes. Solutions by STC has continued to build upon its core telecom position and offers innovative digital services and solutions for enterprises, including cloud and infrastructure services, network and security management services, Big Data and analytics solutions, and Internet of Things (IoT) solutions (such as fleet/asset management and mobile point-of-sale solutions). These solutions complement stc’s considerable systems integration capabilities across several industries. www.solutions.com.sa
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210128005057/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 13:30:00 CEST | Press release
-With this expansion, any variant that results in production of CFTR protein is now included in the indication for ALYFTREK and TRIKAFTA, reinforcing the impact these medicines have, regardless of the location of the variant in the CFTR protein--Approximately 800 more people with CF in the US are now eligible for a CFTR modulator for the first time- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported b
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 13:30:00 CEST | Press release
A Landmark Registrational Study Aiming to Redefine Outcomes in MSS mCRC Which Represents Approximately 95% of Metastatic Colorectal Cancer CasesColorectal Cancer Has Become the Leading Cause of Cancer-related Death in Adults Under Age 50 Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooper
Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 13:19:00 CEST | Press release
Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 13:00:00 CEST | Press release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom